HemoClear™: A Thin Fluid Film Device (TFFD™) for evacuating Blood and eliminating fogging on Surgical and Implant Lenses

S.A. Sinha, A.J. Acharya, N. Herbots, E.J. Culbertson, C.F. Watson, M. Matiski, A.J. Orr, R.B. Bennett-Kennett, A.M. Murphy, B.W. Hughes, A.S. Benitez, T.T. Kutz, D.A. Sell, E.R. Morgan, A.L. Brimhall, R.J. Culbertson
Arizona State University/SiO2 NanoTech, LLC., US

Keywords: fogging, optic, optical, lenses, anti-fog, surgery, medical device accessory, emulsion, hydro-affinity, hydrophilic, hydrophobic, SiO2, scope, blood protein, fibrinogen, infection prevention, scarring, closed body cavity surgery, condensation, bodily fluids


During closed body cavity surgery, the view through the lens of surgical scopes is often obstructed by the condensation of water (fog) and blood on the lens surface; this forces surgeons to repeatedly remove the scope and wipe the lens. Consequently, surgery duration increases (by up to 40%), as does risk of infection and scarring due to removal and reinsertion of the scope, defeating the purpose of closed body cavity surgery. HemoClear™, a Thin Fluid Film Device (TFFD™), is a layered emulsion combining VitreOx™ and fibrinogen. VitreOx™ is an anti-fog TFFD™, free of optical aberration, optically transparent, and super-hydrophilic for up to 48 hours after application on a lens (although it has been formulated to last much longer for non-surgical applications). Our research has demonstrated that fibrinogen can effectively evacuate blood from a lens without interfering with anti-fog activity. Ongoing research seeks to establish the fibrinogen concentration range where blood is effectively evacuated when fibrinogen is combined with VitreOx™. The mixing and layering procedure of HemoClear™ components is tested with simulated in vivo clinical trials to identify the smallest effective dose of fibrinogen that allows for the evacuation of blood while still inhibiting fogging.